Montes-Vera MR, Garrido-Acosta O, Anguiano-Robledo L, Sánchez-Navarrete J, Pérez-Cruz E, Rodríguez-Wong U, Cruz-Rico J, Ruiz-Pérez NJ

Language: Spanish
References: 0
Page: 73-78
PDF size: 0. Kb.

ABSTRACT

Angiogenesis is a process that involves the growth of new blood vessels from pre-existing vasculature. Vascular endothelial growth factor (VEGF) is the key signal used to promote growth of blood vessels. Bevacizumab is a humanized monoclonal antibody that inhibits the angiogenesis process. This review has the purpose to expose some pharmaceutical aspects of bevacizumab.